Micro-Scale Control of Oligodendrocyte Morphology and Myelination by the Intellectual Disability-Linked Protein Acyltransferase ZDHHC9

Reviewer #1 (Public Review):

In this work Jeong and colleagues focus on exploring the role of the acyltransferase ZDHHC9 in myelinating OLs in particular in the palmitoylation of several myelin proteins. After confirming the specific enrichment of the Zdhhc9 transcript in mouse and human OLs, the authors examine the subcellular localization of the protein in vitro and observed that in comparison with other isoforms, ZDHHC9 localizes at OLs cell bodies and at discrete puncta in the processes. These observations (Figures 1 and 2) led the authors to hypothesize that ZDHHC9 plays an important role in myelination. No gross changes were detected in OL development in Zdhhc9 KO mice and analyses from P28 Zdhhc9 KO mice crossed with Mobp-EGFP reporter mice did not show changes in EGFP+ OL differentiation (Figure 3). However, and given the observed subcellular localization of ZDHHC9 in OL processes (Figure 2) and the observation that the percentage of unmyelinated axons is increased in Zdhhc9 KO (Figure 6), early time points to examine the differentiated pools of OLs and their capacity to extend processes/contact axons need to be considered.

Maturation of OL in Zdhhc9 KO was examined by crossing Zdhhc9 KO with Pdgfra-CreER; R26- EGFP and following the newly EGFP-labelled OPCs following tamoxifen administration. No changes in the numbers of EGFP+ OL were detected. The authors concluded that the loss of ZDHHC9 does not alter oligodendrogenesis in either the young or mature CNS. The authors observed defects in Zdhhc9 KO OL protrusions that they attributed to abnormal OL membrane expansion (Fig 4 and 5). Can they show evidence for this?

The authors report that Zdhhc9 KO primary and secondary branches in OL were longer, some contained spheroid-like swellings and the OL protrusion complexity was higher. However, these data is partially contradictory to what they show in OL differentiation experiments in vitro (Fig 7). There is also no evidence for increased membrane expansion in Zdhhc9 knockdown myelin forming cells in culture. How to reconcile this?

Reviewer #2 (Public Review):

This study provides an in-depth exploration of the impact of X-linked ZDHHC9 gene mutations on cognitive deficits and epilepsy, with a particular focus on the expression and function of ZDHHC9 in myelin-forming oligodendrocytes (OLs). These findings offer crucial insights into understanding ZDHHC9-related X-linked intellectual disability (XLID) and shed light on the regulatory mechanisms of palmitoylation in myelination. The experimental design and analysis of results are convincing, providing a valuable reference for further research in this field. However, upon careful review, I believe the article still needs further improvement and supplementation in the following aspects:

(1) Regarding the subcellular localization experiment of ZDHHC9 mutants in OL, it is currently limited to in vitro cultured OL, lacking validation in vivo OL or myelin sheath. Additionally, it is necessary to investigate whether the abnormal subcellular localization of ZDHHC9 mutants affects their enzyme activity and palmitoylation modification of substrate proteins.

(2) The experimental period (P21+21 days) using genetic labeling to track the development of myelinating cells may not be long enough. It is recommended to extend the observation time and analyze at more time points to more comprehensively reflect the impact of Zdhhc9 KO.

(3) The author speculates that Zdhhc9 may regulate myelination by affecting the membrane localization of specific myelin proteins, but lacks direct experimental evidence to support this. It is suggested to detect the expression and distribution of relevant proteins in the myelin of Zdhhc9 KO mice.

(4) Although the article mentions the association of Zdhhc9 with intellectual disabilities, it does not involve behavioral analysis of Zdhhc9 KO mice. It is recommended to supplement some behavioral experimental data to support the important role of Zdhhc9 in maintaining normal cognitive function, enhancing the clinical relevance of the article.

(5) For the abnormal myelination observed in Zdhhc9 KO mice, including unmyelinated large-diameter axons and excessively myelinated small-diameter axons, the article lacks in-depth research and explanation on the exact mechanism and mode of action of ZDHHC9 in regulating myelination.

(6) The function of ZDHHC9 in OL may be related to the Golgi apparatus, but its exact role in these structures is still unclear. It is suggested to discuss in more detail the role of ZDHHC9 in the Golgi apparatus in the discussion section.

(7) More experimental support and in-depth research are needed on the detailed mechanism of how ZDHHC9 and Golga7 cooperatively regulate MBP palmitoylation, and how this decrease in palmitoylation level leads to myelination defects.

In summary, it is recommended that the authors address the above issues through additional experiments and improved discussions to further strengthen the credibility and clinical relevance of the article.